We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Seeking to make Part 11 "less prescriptive," the FDA is calling on industry for advice as the agency considers whether to revise the rule or issue additional guidance documents.
The FDA has broken its silence on Part 11 for the first time since issuing a guidance last August by calling on industry to comment on how to make Part 11 "less prescriptive," either by revising the rule or issuing additional guidance documents.